Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF - PubMed (original) (raw)
Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
J Holash et al. Science. 1999.
Abstract
In contrast with the prevailing view that most tumors and metastases begin as avascular masses, evidence is presented here that a subset of tumors instead initially grows by coopting existing host vessels. This coopted host vasculature does not immediately undergo angiogenesis to support the tumor but instead regresses, leading to a secondarily avascular tumor and massive tumor cell loss. Ultimately, however, the remaining tumor is rescued by robust angiogenesis at the tumor margin. The expression patterns of the angiogenic antagonist angiopoietin-2 and of pro-angiogenic vascular endothelial growth factor (VEGF) suggest that these proteins may be critical regulators of this balance between vascular regression and growth.
Similar articles
- New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.
Holash J, Wiegand SJ, Yancopoulos GD. Holash J, et al. Oncogene. 1999 Sep 20;18(38):5356-62. doi: 10.1038/sj.onc.1203035. Oncogene. 1999. PMID: 10498889 Review. - Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2.
Vajkoczy P, Farhadi M, Gaumann A, Heidenreich R, Erber R, Wunder A, Tonn JC, Menger MD, Breier G. Vajkoczy P, et al. J Clin Invest. 2002 Mar;109(6):777-85. doi: 10.1172/JCI14105. J Clin Invest. 2002. PMID: 11901186 Free PMC article. - Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
Zhang L, Yang N, Park JW, Katsaros D, Fracchioli S, Cao G, O'Brien-Jenkins A, Randall TC, Rubin SC, Coukos G. Zhang L, et al. Cancer Res. 2003 Jun 15;63(12):3403-12. Cancer Res. 2003. PMID: 12810677 - Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF).
Visconti RP, Richardson CD, Sato TN. Visconti RP, et al. Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8219-24. doi: 10.1073/pnas.122109599. Epub 2002 Jun 4. Proc Natl Acad Sci U S A. 2002. PMID: 12048246 Free PMC article. - Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development.
Gale NW, Yancopoulos GD. Gale NW, et al. Genes Dev. 1999 May 1;13(9):1055-66. doi: 10.1101/gad.13.9.1055. Genes Dev. 1999. PMID: 10323857 Review. No abstract available.
Cited by
- Flavonoid-Mediated Suppression of Tumor Angiogenesis: Roles of Ang-Tie/PI3K/AKT.
Saini S, Tuli HS, Saini RV, Saini AK, Sak K, Kaur D, Shahwan M, Chauhan R, Chauhan A. Saini S, et al. Pathophysiology. 2024 Oct 12;31(4):596-607. doi: 10.3390/pathophysiology31040043. Pathophysiology. 2024. PMID: 39449525 Free PMC article. Review. - Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes.
Sun Y, Yinwang E, Wang S, Wang Z, Wang F, Xue Y, Zhang W, Zhao S, Mou H, Chen S, Jin L, Li B, Ye Z. Sun Y, et al. Mol Cancer. 2024 Sep 9;23(1):193. doi: 10.1186/s12943-024-02104-w. Mol Cancer. 2024. PMID: 39251981 Free PMC article. Review. - Targeting the tumour vasculature: from vessel destruction to promotion.
Guelfi S, Hodivala-Dilke K, Bergers G. Guelfi S, et al. Nat Rev Cancer. 2024 Oct;24(10):655-675. doi: 10.1038/s41568-024-00736-0. Epub 2024 Aug 29. Nat Rev Cancer. 2024. PMID: 39210063 Review. - Small molecule inhibitors of the VEGF and tyrosine kinase for the treatment of cervical cancer.
Sarwar F, Ashhad S, Vimal A, Vishvakarma R. Sarwar F, et al. Med Oncol. 2024 Jul 10;41(8):199. doi: 10.1007/s12032-024-02446-x. Med Oncol. 2024. PMID: 38985225 Review. - MAPK4 facilitates angiogenesis by inhibiting the ERK pathway in non-small cell lung cancer.
Chen J, Yang J, Liu Y, Zhao X, Zhao J, Tang L, Guo M, Zhou Y, Chen C, Li D, Wen Z, Liang G, Xu L. Chen J, et al. Cancer Innov. 2024 Apr 16;3(3):e117. doi: 10.1002/cai2.117. eCollection 2024 Jun. Cancer Innov. 2024. PMID: 38947754 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources